Enzyme Acquires Myso Finance and Expands to Solana in Major 2024 Growth

Enzyme Protocol is partnering with Rayls Labs as a launch partner, bringing institutional-grade tokenized fund infrastructure to the platform from day one. **Key Details:** - Enzyme's Onyx and Myso products will be available on Rayls at launch - The partnership provides institutional-grade infrastructure for tokenized funds - Onyx enables fund managers to access lending markets like Morpho and Fluid directly within tokenized fund structures This collaboration aims to reduce infrastructure constraints for early-stage investment opportunities in decentralized asset management. Read the full announcement: [enzyme.finance/blog-posts/enzyme-arrives-on-rayls](https://enzyme.finance/blog-posts/enzyme-arrives-on-rayls)

**Private credit operations are now fully executable on-chain.** Credilabs and Turtle have launched infrastructure built on Enzyme Protocol that handles loan mechanics, collateral management, and settlement flows entirely on-chain with integrated compliance controls. **Key innovation: Direct settlement architecture** - Payment proceeds route directly from merchant acquirers to tokenized credit funds - Borrowers are removed from the payment loop entirely - Automates short-duration receivables flow - Secures investor returns through programmatic enforcement This represents a shift from traditional private credit operations to blockchain-native infrastructure where loan terms, collateral requirements, and payment flows are enforced by smart contracts rather than manual processes. The infrastructure is now live and available for other asset managers looking to bring real-world yield strategies on-chain through Enzyme's Onyx product.

**Enzyme Onyx** addresses different protocol needs across three key stages: - **Pre-TGE**: Early participation incentives to build community - **Post-TGE**: Strengthen Total Value Locked (TVL) after token launch - **Mature stage**: Manage liquidity across multiple assets including stablecoins and liquid staking tokens The platform provides structured, on-chain strategies that protocols can adopt when timing is right for their development phase. Each stage requires different tooling approaches, but most protocols eventually need comprehensive on-chain financial infrastructure. [Explore Onyx](https://enzyme.finance/products/onyx?utm_source=x&utm_medium=organic&utm_content=post)

**Multi-chain complexity solved**: As investment products expand across different blockchains, reporting becomes increasingly complex for asset managers. **Automated data sourcing**: Chainlink's CRE (Crypto Reporting Engine) automatically pulls and verifies NAV and performance data from: - On-chain sources - Centralized finance platforms - Traditional financial systems **Pain point addressed**: The solution eliminates manual reporting work that previously required tracking assets across multiple chains and platforms. **Verification built-in**: All data is automatically verified, reducing errors and ensuring accuracy for compliance and investor reporting.

Enzyme.Myso is advancing DeFi with institutional-grade on-chain options trading. The platform offers: - Native on-chain options strategies - Fully auditable transaction flows - Infrastructure designed for DAOs and institutions **Real-world implementation**: Compound DAO recently integrated covered calls into their treasury strategy using Enzyme.Myso, targeting approximately 15% APY while maintaining controlled risk exposure. This development signals a shift in how DAOs can optimize idle capital through sophisticated options strategies. *Learn more at* [Enzyme Finance](http://enzyme.finance/products/myso)